2026-04-13T18:25:48Zhttps://recercat.cat/oai/request

oai:recercat.cat:10230/529902025-12-24T08:57:10Zcom_2072_6col_2072_452952

00925njm 22002777a 4500 dc Agache, Ioana author Akdis, Cezmi A. author Akdis, Mubeccel author Brockow, Knut author Chivato, Tomas author Del Giacco, Stefano author Eiwegger, Thomas author Eyerich, Kilian author Giménez Arnau, Anna Maria author Gutermuth, Jan author Guttman-Yassky, Emma author Maurer, Marcus author Ogg, Graham author Ong, Peck Y. author O'Mahony, Liam author Schwarze, Jürgen author Warner, Amena author Werfel, Thomas author Palomares, Oscar author Jutel, Marek author 2022-05-05T07:40:56Z 2022-05-05T07:40:56Z 2022 Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1 R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed. GRADE Chronic spontaneous urticaria Guidelines Omalizumab EAACI biologicals guidelines-omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old